Last reviewed · How we verify
mRNA-1273
mRNA-1273 is a lipid nanoparticle-formulated messenger RNA vaccine that encodes the SARS-CoV-2 spike protein, instructing cells to produce the antigen and trigger adaptive immune responses.
mRNA-1273 is a lipid nanoparticle-formulated messenger RNA vaccine that encodes the SARS-CoV-2 spike protein, instructing cells to produce the antigen and trigger adaptive immune responses. Used for COVID-19 prevention in adults and pediatric populations, COVID-19 booster vaccination.
At a glance
| Generic name | mRNA-1273 |
|---|---|
| Also known as | Elasomeran, Imelasomeran, Davesomeran, Spikevax, Spikevax bivalent |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein (S protein) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine delivers synthetic mRNA wrapped in lipid nanoparticles into host cells, where it is translated into spike protein. This protein is presented to the immune system, stimulating both CD8+ T-cell and B-cell responses, including production of neutralizing antibodies against SARS-CoV-2. The mRNA is subsequently degraded through normal cellular pathways.
Approved indications
- COVID-19 prevention in adults and pediatric populations
- COVID-19 booster vaccination
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (PHASE4)
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) (PHASE4)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1273 CI brief — competitive landscape report
- mRNA-1273 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI